13 results on '"Dana Ben-Hur"'
Search Results
2. COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience
- Author
-
Lev Lichtenstein, Benjamin Koslowsky, Ami Ben Ya’acov, Irit Avni-Biron, Baruch Ovadia, Ofer Ben-Bassat, Timna Naftali, Uri Kopylov, Yael Haberman, Hagar Banai Eran, Rami Eliakim, Adi Lahat-Zok, Ayal Hirsch, Eran Zittan, Nitsan Maharshak, Matti Waterman, Eran Israeli, Idan Goren, Jacob E. Ollech, Henit Yanai, Bella Ungar, Benjamin Avidan, Dana Ben Hur, Bernardo Melamud, Ori Segol, Zippora Shalem, Iris Dotan, Selwyn H. Odes, Shomron Ben-Horin, Yf’at Snir, Yael Milgrom, Efrat Broide, Eran Goldin, Shmuel Delgado, Yulia Ron, Nathaniel Aviv Cohen, Eran Maoz, Maya Zborovsky, Safwat Odeh, Naim Abu Freha, Eyal Shachar, Yehuda Chowers, Tal Engel, Hila Reiss-Mintz, Arie Segal, Adar Zinger, and Ariella Bar-Gil Shitrit
- Subjects
COVID-19 ,Crohn’s disease ,ulcerative colitis ,inflammatory bowel disease ,biological drugs ,immune suppression ,Medicine - Abstract
Background: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, immune-mediated inflammatory bowel diseases (IBD) affecting millions of people worldwide. IBD therapies, designed for continuous immune suppression, often render patients more susceptible to infections. The effect of the immune suppression on the risk of coronavirus disease-19 (COVID-19) is not fully determined yet. Objective: To describe COVID-19 characteristics and outcomes and to evaluate the association between IBD phenotypes, infection outcomes and immunomodulatory therapies. Methods: In this multi-center study, we prospectively followed IBD patients with proven COVID-19. De-identified data from medical charts were collected including age, gender, IBD type, IBD clinical activity, IBD treatments, comorbidities, symptoms and outcomes of COVID-19. A multivariable regression model was used to examine the effect of immunosuppressant drugs on the risk of infection by COVID-19 and the outcomes. Results: Of 144 IBD patients, 104 (72%) were CD and 40 (28%) were UC. Mean age was 32.2 ± 12.6 years. No mortalities were reported. In total, 94 patients (65.3%) received biologic therapy. Of them, 51 (54%) at escalated doses, 10 (11%) in combination with immunomodulators and 9 (10%) with concomitant corticosteroids. Disease location, behavior and activity did not correlate with the severity of COVID-19. Biologics as monotherapy or with immunomodulators or corticosteroids were not associated with more severe infection. On the contrary, patients receiving biologics had significantly milder infection course (p = 0.001) and were less likely to be hospitalized (p = 0.001). Treatment was postponed in 34.7% of patients until recovery from COVID-19, without consequent exacerbation. Conclusion: We did not witness aggravated COVID-19 outcomes in patients with IBD. Patients treated with biologics had a favorable outcome.
- Published
- 2022
- Full Text
- View/download PDF
3. The Association Between Opioid Use and Opioid Type and the Clinical Course and Outcomes of Acute Pancreatitis
- Author
-
Adi, Elias, Alexander, Korytny, Amir, Klein, Yara, Khoury, Dana, Ben Hur, Eyal, Braun, Zaher S, Azzam, and Itai, Ghersin
- Subjects
Adult ,Pain, Postoperative ,Morphine ,Hepatology ,Endocrinology, Diabetes and Metabolism ,Analgesics, Non-Narcotic ,Opioid-Related Disorders ,Analgesics, Opioid ,Endocrinology ,Pancreatitis ,Acute Disease ,Internal Medicine ,Humans ,Retrospective Studies - Abstract
Basic science studies suggest that opioids aggravate disease severity and outcomes in acute pancreatitis. We sought to determine the association of opioid use and opioid type with the clinical course and outcome of acute pancreatitis.In this retrospective single-center observational study, we included all adult patients admitted with acute pancreatitis between 2008 and 2021. Patients were classified into 3 groups based on analgesia type: morphine, noonmorphine opioid, and nonopioid.We included 2308 patients. Of the patients, 343 (14.9%) were treated with morphine, 733 (31.8%) were treated with nonmorphine opioids, and 1232 (53.4%) patients were in the nonopioid group. The incidence of 30-day mortality did not differ significantly between study groups: 3.9%, 2.9%, and 4.4% in the nonopioid, nonmorphine-opioid, and morphine groups, respectively ( P = 0.366).In multivariate analysis, the composite end point consisting of 30-day mortality, invasive ventilation, emergent abdominal surgery, and need for vasopressors was significantly more likely to occur in the morphine group than in the nonopioid group (adjusted odds ratio, 1.69; 95% confidence interval, 1.1-2.598; P = 0.01).Mortality among acute pancreatitis patients did not differ significantly between patients receiving morphine, nonmorphine opioids, and nonopioids. However, morphine treatment was associated with higher rates of some serious adverse events.
- Published
- 2022
4. Does early corticosteroid therapy affect prognosis in IBD patients hospitalized with Clostridioides difficile infection?
- Author
-
Haneen Daoud, Dana Ben Hur, Matti Waterman, Haggai Bar-Yoseph, and Yehuda Chowers
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Subgroup analysis ,Kaplan-Meier Estimate ,Patient Readmission ,Inflammatory bowel disease ,Time-to-Treatment ,03 medical and health sciences ,0302 clinical medicine ,Adrenal Cortex Hormones ,Risk Factors ,Cause of Death ,Internal medicine ,Humans ,Medicine ,Colectomy ,Retrospective Studies ,business.industry ,Proportional hazards model ,Mortality rate ,Gastroenterology ,Retrospective cohort study ,Middle Aged ,Hepatology ,Inflammatory Bowel Diseases ,Prognosis ,medicine.disease ,Anti-Bacterial Agents ,030220 oncology & carcinogenesis ,Bacteremia ,Clostridium Infections ,Female ,030211 gastroenterology & hepatology ,business - Abstract
Corticosteroids (CS) therapy to Clostridioides difficile infection (CDI) in inflammatory bowel disease (IBD) flares may worsen CDI outcomes. Assess the impact of early CS exposure on outcomes of IBD patients diagnosed with CDI. Retrospective study of IBD patients admitted with first-time CDI between 2002 and 2018. Comparisons were made based on CS exposure 48 h from admission. Patients were further subdivided to 5 groups based on CS-antibiotics temporal exposure. The primary outcome was all-cause mortality or colectomy within 3 months. Secondary outcomes were colectomy and mortality rates at 1 year, length of stay, readmissions, bacteremia, and diarrhea improvement by day 7/discharge. Cox proportional hazard model and Kaplan-Meier curves were used to assess the effects on survival. Logistic and ordinal regressions were used to assess primary and secondary outcomes. One hundred thirteen patients (64 CD, 46 UC, and 3 IBDU) were included, 82 (72.5%) received early CS. At baseline, CRP was significantly lower and albumin was higher in the group not exposed to early CS. At 3 months, 4 (4.8%) patients required colectomy and 6 (5.8%) died (p = NS). Length of stay was significantly reduced among patients not exposed to early CS. All other endpoints were not associated with CS exposure. In subgroup analysis, the primary outcome was not significantly different among the sub-groups. Mortality rate at 1 year was significantly lower in patients who did not receive antibiotics for CDI. Early CS therapy in IBD patients hospitalized with CDI is not associated with worse clinical outcomes. However, additional prospective research is required.
- Published
- 2020
5. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
- Author
-
Henit Yanai, Anna Kagramanova, Oleg Knyazev, João Sabino, Shana Haenen, Gerassimos J Mantzaris, Katerina Mountaki, Alessandro Armuzzi, Daniela Pugliese, Federica Furfaro, Gionata Fiorino, David Drobne, Tina Kurent, Sharif Yassin, Nitsan Maharshak, Fabiana Castiglione, Roberto de Sire, Olga Maria Nardone, Klaudia Farkas, Tamas Molnar, Zeljko Krznaric, Marko Brinar, Elena Chashkova, Moran Livne Margolin, Uri Kopylov, Cristina Bezzio, Ariella Bar-Gil Shitrit, Milan Lukas, María Chaparro, Marie Truyens, Stéphane Nancey, Triana Lobaton, Javier P Gisbert, Simone Saibeni, Péter Bacsúr, Peter Bossuyt, Julien Schulberg, Frank Hoentjen, Chiara Viganò, Andrea Palermo, Joana Torres, Joana Revés, Konstantinos Karmiris, Magdalini Velegraki, Edoardo Savarino, Panagiotis Markopoulos, Eftychia Tsironi, Pierre Ellul, Cristina Calviño Suárez, Roni Weisshof, Dana Ben-Hur, Timna Naftali, Carl Eriksson, Ioannis E Koutroubakis, Kalliopi Foteinogiannopoulou, Jimmy K Limdi, Eleanor Liu, Gerard Surís, Emma Calabrese, Francesca Zorzi, Rafał Filip, Davide Giuseppe Ribaldone, Yifat Snir, Idan Goren, Hagar Banai-Eran, Yelena Broytman, Hadar Amir Barak, Irit Avni-Biron, Jacob E Ollech, Iris Dotan, and Maya Aharoni Golan
- Subjects
Adult ,Male ,Crohn’s disease ,Biological Products ,post-operative recurrence ,Gastroenterology ,General Medicine ,Biologics ,biologics ,Young Adult ,Treatment Outcome ,Post-operative recurrence ,Crohn Disease ,Medicine and Health Sciences ,Humans ,Female ,Tumor Necrosis Factor Inhibitors ,Ustekinumab ,03.02.18. Endokrinológia és anyagcserebetegségek (benne cukorbetegség, hormonok) ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Retrospective Studies - Abstract
Background Endoscopic-post-operative-recurrence [ePOR] in Crohn’s disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour necrosis factor [anti-TNF] therapy to vedolizumab [VDZ] and ustekinumab [UST] in a real-world setting. Methods A retrospective multicentre study of CD-adults after curative ICR on early prophylaxis was undertaken. ePOR was defined as a Rutgeerts score [RS] ≥ i2 or colonic-segmental-SES-CD ≥ 6. Multivariable logistic regression was used to evaluate risk factors, and inverse probability treatment weighting [IPTW] was applied to compare the effectiveness between agents. Results The study included 297 patients (53.9% males, age at diagnosis 24 years [19–32], age at ICR 34 years [26–43], 18.5% smokers, 27.6% biologic-naïve, 65.7% anti-TNF experienced, 28.6% two or more biologics and 17.2% previous surgery). Overall, 224, 39 and 34 patients received anti-TNF, VDZ or UST, respectively. Patients treated with VDZ and UST were more biologic experienced with higher rates of previous surgery. ePOR rates within 1 year were 41.8%. ePOR rates by treatment groups were: anti-TNF 40.2%, VDZ 33% and UST 61.8%. Risk factors for ePOR at 1 year were: past-infliximab (adjusted odds ratio [adj.OR] = 1.73 [95% confidence interval, CI: 1.01–2.97]), past-adalimumab [adj.OR = 2.32 [95% CI: 1.35-4.01] and surgical aspects. After IPTW, the risk of ePOR within 1 year of VDZ vs anti-TNF or UST vs anti-TNF was comparable (OR = 0.55 [95% CI: 0.25–1.19], OR = 1.86 [95% CI: 0.79–4.38]), respectively. Conclusion Prevention of ePOR within 1 year after surgery was successful in ~60% of patients. Patients treated with VDZ or UST consisted of a more refractory group. After controlling for confounders, no differences in ePOR risk were seen between anti-TNF prophylaxis and other groups.
- Published
- 2022
6. Sa1324: THE ASSOCIATION BETWEEN OPIOID USE AND OPIOID TYPE AND THE CLINICAL COURSE AND OUTCOMES OF ACUTE PANCREATITIS
- Author
-
Adi Elias, Alexander Korytny, Amir Klein, Yara Khoury, Dana Ben Hur, Zaher S. Azzam, and Itai Ghersin
- Subjects
Hepatology ,Gastroenterology - Published
- 2022
7. Su1572: PATTERNS OF MEDICATION USE IN ELDERLY-ONSET INFLAMMATORY BOWEL DISEASE (IBD) - A POPULATION BASED STUDY FROM THE EPIDEMIOLOGIC DATABASE OF THE ISRAEL IBD RESARCH NUCLEUS (EPI-IIRN)
- Author
-
Dana Ben Hur, Guy Issaschar, Ran Moshe, Rona Lujan, Gili Focht, Revital Kariv, Eran Matz, Dan Turner, Gabriel D. Pinto, and Matti Waterman
- Subjects
Hepatology ,Gastroenterology - Published
- 2022
8. Tu1068: THE ASSOCIATION BETWEEN LOW BODY-MASS INDEX AND SERIOUS ENDOSCOPIC ADVERSE EVENTS
- Author
-
Netta Glaubach, Dana Ben Hur, Alexander Korytny, Yonatan Isenberg, Yosuf Laham, and Haggai Bar-Yoseph
- Subjects
Hepatology ,Gastroenterology - Published
- 2022
9. [COMPARISON OF QUALITY OF COLONOSCOPY IN AN ACADEMIC HOSPITAL VS. A COMMUNITY HOSPITAL OUTPATIENT SERVICE]
- Author
-
Badira, Makhoul, Muhammad, Khatib, Dana, Ben Hur, and Jesse, Lachter
- Subjects
Fentanyl ,Academic Medical Centers ,Ambulatory Care ,Humans ,Hospitals, Community ,Colonoscopy ,Retrospective Studies - Abstract
Extensive use of colonoscopy in hospitals and community clinics has highlighted the need to assess the quality of the procedures in order to reduce costs and increase their efficiency.This institutional review board (IRB)-approved study aimed to compare the quality of colonoscopies performed in a teaching hospital to those performed at a community health service.Demographic information, time of procedure, indications, quality of bowel preparation, premedication, depth of examination, polyp detection, biopsies and followup recommendations were retrospectively obtained from 700 colonoscopy reports from the Rambam Healthcare Campus and 824 colonoscopy reports from Elisha. This data was compared to relevant literature benchmarks.There was no statistically significant difference between the hospital vs. community endoscopy services in the patients' demographics, depth of examination (92.4% vs. 94.1% complete), polyp detection rate (29.1% vs. 26.8%) and biopsies in patients with diarrhea (75% vs. 67%). Indications for colonoscopy differed: gastrointestinal bleeding was more common at the hospital, while screening was more common in the community. Premedication varied: more fentanyl and dormicum and less propofol were used in the community. Good bowel preparation was more frequent in the community (68.8% vs. 47.2% in hospital, p0.0001). Follow-up recommendations were documented more often in the community (74% vs. 53% in hospital, p0.0001). The range for many quality indicators (QIs) varied greatly amongst physicians.Remediation of weaker areas seems feasible through upgrading electronic medical records and increasing awareness of quality indicators (Qis). Colonoscopies performed in both hospital and community services were of good quality compared to the relevant literature, with significant variations in some QIs.
- Published
- 2017
10. Su1931 – Does Corticosteroid Therpay Affect Prognosis in Inflammatory Bowel Disease Patients Hospitalized with Clostridium Difficile Infection?
- Author
-
Haggai Bar-Yoseph, Haneen Daoud, Dana Ben Hur, Matti Waterman, and Yehuda Chowers
- Subjects
medicine.medical_specialty ,Hepatology ,medicine.drug_class ,business.industry ,Gastroenterology ,Clostridium difficile ,medicine.disease ,Affect (psychology) ,Inflammatory bowel disease ,Internal medicine ,medicine ,Corticosteroid ,business - Published
- 2019
11. Hospital Care Efficiency and the SMART (Specific, Measurable, Agreed, Required, and Timely) Medicine Initiative
- Author
-
Nirit Grushko, Ali Yahia, Vera Belsky, Dana Ben-Hur, Gidon Berger, Ronen Zalts, and Jasmin Khateeb
- Subjects
Models, Educational ,Organizational efficiency ,Cost effectiveness ,Lactate dehydrogenase measurement ,MEDLINE ,L-Lactate dehydrogenase ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Natriuretic Peptide, Brain ,Unnecessary Procedure ,Internal Medicine ,medicine ,Humans ,030212 general & internal medicine ,Israel ,Creatine Kinase ,Diagnostic Techniques and Procedures ,Inpatients ,L-Lactate Dehydrogenase ,business.industry ,medicine.disease ,Creatine kinase measurement ,Troponin ,Hospital care ,Amylases ,Patient Care ,Medical emergency ,business ,Delivery of Health Care ,Blood Chemical Analysis - Published
- 2016
12. [Quality indicators in colonoscopy]
- Author
-
Jesse, Lachter and Dana, Ben Hur
- Subjects
Adult ,Aged, 80 and over ,Diarrhea ,Male ,Colonic Polyps ,Colonoscopy ,Middle Aged ,Inflammatory Bowel Diseases ,Benchmarking ,Sex Factors ,Humans ,Female ,Israel ,Aged ,Follow-Up Studies ,Quality Indicators, Health Care ,Retrospective Studies - Abstract
Extensive use of colonoscopy has highlighted the need to assess the quality of the procedures in order to reduce costs and increase efficiency.(1) To assess quality indicators of colonoscopies performed by specialist physicians in Rambam HeaLth Care Campus; (2) To improve the quality of colonoscopies using the data collected.Data was collected retrospectively from reports of 700 colonoscopies performed by 7 gastroenterology specialists in Rambam Health Care Campus. The data collected was compared to relevant Literature benchmarks for accepted quality indicators.A total of 95.3% of procedures had appropriate indications. Good or excellent bowel preparation was documented for 57.4% of procedures with a range for individual physicians from 18.2%-84%. Completion rate was 92.4% (range 89.9%-97%). Overall polyp detection rate was 29.1% (range 17%-45%). Polyp detection rate in screening colonoscopies was 13.2% for women and 26.1% for men. Biopsies were taken in 90.3% of colonoscopies performed for inflammatory bowel disease (IBD) follow-up and in 75% of colonoscopies performed in patients with chronic diarrhea. Follow-up recommendations were noted in 82.6% of procedures with any indication for follow-up (range 70%-92.5%).Colonoscopies are performed in Rambam Health Care Campus in an effective manner with regard to completion rate and polyp detection. High rates of intermediate or poor bowel preparation, suboptimal rates of taking biopsies and making follow-up recommendations were noted. Significant variations among participating physicians were noted. Conclusions led to operative changes in practice, including improving computerized reports, standardizing assessments of preparation and initiating a continuous quality improvement program.
- Published
- 2011
13. Tu1158 Evaluating Adalimumab Drug and Antibody Levels As Predictors of Clinical and Laboratory Response in Crohn's Disease Patients
- Author
-
Shomron Ben-Horin, Yoav Mazor, Uri Kopylov, Ronit Almog, Matti Waterman, Dana Ben Hur, and Yehuda Chowers
- Subjects
Drug ,medicine.medical_specialty ,Crohn's disease ,Hepatology ,business.industry ,media_common.quotation_subject ,Gastroenterology ,Antibody level ,medicine.disease ,Internal medicine ,Immunology ,Adalimumab ,medicine ,business ,medicine.drug ,media_common - Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.